IQHQ Inc., a premier life sciences real estate development company, announced that it has successfully completed a second $1.7 billion equity raise from new and existing strategic partners.

With two successful rounds of financing complete, IQHQ is well funded and well positioned to pursue the company’s dynamic development pipeline that includes an anticipated 4.4 million square feet of cutting-edge life science projects in Boston, San Francisco and San Diego – in addition to allowing IQHQ to capitalize on the company’s large and growing pipeline of high quality life science real estate opportunities.

“We are honored by the trust placed in us by our shareholders for the completion of this significant capital raise, which validates IQHQ’s solid strategy, our exceptional team, and our success in identifying and securing premier life science projects and developments in top markets,” said Steve Rosetta, CEO of IQHQ. “It is important to take this opportunity to reflect on all that we have accomplished since our initial raise, and the most exciting part is that we are just getting started.”

The raise includes a private placement financing to qualified institutional buyers under Rule 144A of the Securities Act of 1933 and project specific equity investments. This $1.7 billion raise comes just nine months after IQHQ’s successful completion of a $770 million initial capital raise.

Following the initial raise, IQHQ completed strategic acquisitions of major development sites and assets in thriving life science markets including Greater Boston, San Francisco and most recently in San Diego – the Research and Development District (The RaDD).

“Interest in the offering was exceptionally strong due to the incredible momentum that IQHQ has achieved since its formation earlier this year, and the unmatched track record of its senior management team in delivering strong investor performance and scaling public REITs,” said Jamie Graff, Managing Director, Co-Head of Real Estate of Raymond James. “During a turbulent year, IQHQ’s focus on the commercial life science sector has been a winning strategy as the market shows no signs of slowing down – quite the opposite, despite the economic headwinds associated with the pandemic, life science real estate has remained steady and all indications point to continued growth.”

Source: Business Wire

Can’t stop reading? Read more